Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Adam Lindsay

Sports Medicine Bend, OR Medical Doctor

NPI 1811371669 CMS profile 4220739

2200 Ne Neff Rd Ste 200, Bend, OR 97701

Open in the dashboard

General payments

$71,095

194 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Lindsay of Bend, OR is reported in the CMS Open Payments database as having received $71,095 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,511 34
2024 General $6,266 38
2023 General $2,545 27
2022 General $8,606 49
2021 General $18,682 42
2020 General $25,484 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Lindsay
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Adam Lindsay were reported at $9,511. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Adam Lindsay Sports Medicine median Middle half National median
2019 $0 $1,176 $199–$4,249 $163
2020 $25,484 $708 $96–$2,890 $114
2021 $18,682 $1,213 $152–$3,994 $132
2022 $8,606 $1,230 $159–$3,998 $149
2023 $2,545 $584 $146–$2,836 $160
2024 $6,266 $628 $163–$3,168 $164
2025 $9,511 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Arthrex, Inc. $26,842 41 payments
  2. Smith+Nephew, Inc. $14,994 46 payments
  3. Stryker Corporation $10,977 51 payments
  4. Gemini Mountain Medical, LLC $6,972 10 payments
  5. Djo, LLC $5,000 4 payments
  6. Encore Medical, LP $2,694 10 payments
  7. Zimmer Biomet Holdings, Inc. $2,516 15 payments
  8. DePuy Synthes Sales Inc. $375 5 payments
  9. Steelhead Surgical Inc $289 6 payments
  10. Shoulder Innovations, Inc. $280 2 payments
  11. Other $156 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $25,000 5 payments
  2. Education $20,167 14 payments
  3. Travel and Lodging $13,147 42 payments
  4. Food and Beverage $7,531 130 payments
  5. Consulting Fee $5,250 3 payments
Products named General payments · program years 2020–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $6,495 18 payments
  2. TORNIER PERFORM REVERSED GLENOID $4,313 2 payments
  3. AEQUALIS PERFORM $2,382 14 payments
  4. DJO SURGICAL $1,873 6 payments
  5. Bioinductive Implant with Arthroscopic Delivery System - Medium $1,683 13 payments
  6. Mini-Open Latarjet $1,645 10 payments
  7. MICRORAPTOR Sports Med Hip $1,421 6 payments
  8. MICRORAPTOR Sports Med Hip $1,289 5 payments
  9. Q-FIX $1,289 5 payments
  10. ULTRABRAID $1,289 5 payments
  11. Other $12,011 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

393

Median for Orthopedic Surgery: 203

Drug cost

$1,679

Median for Orthopedic Surgery: $1,433

Branded share of claims

5.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 101 $324
Mupirocin Generic 48 $300
Gabapentin Generic 39 $202
Methocarbamol Generic 60 $165
Ondansetron Hcl Generic 54 $155
Ondansetron Odt Ondansetron Brand 23 $142
Meloxicam Generic 12 $126
Cephalexin Generic 14 $100
Methylprednisolone Generic 16 $69
Tramadol Hcl Generic 15 $54

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$164,769

Of which drugs: $7,468

Medicare patients

277

Average age 73

Services billed

1,605

163 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 69%
High blood pressure 62%
Depression 30%
Ischemic heart disease 26%
Osteoporosis 25%
Diabetes 21%
Heart failure 16%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 46 253 $195

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record